MCRB Seres Therapeutics Inc

Price (delayed)

$1.04

Market cap

$134.43M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.12

Enterprise value

$168.61M

Seres Therapeutics, Inc., is a leading microbiome therapeutics platform company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to ...

Highlights
The EPS has soared by 52% YoY and by 10% QoQ
Seres Therapeutics's net income has increased by 39% YoY and by 8% from the previous quarter
MCRB's debt has surged by 179% year-on-year
The equity has shrunk by 167% QoQ and by 122% YoY

Key stats

What are the main financial stats of MCRB
Market
Shares outstanding
129.26M
Market cap
$134.43M
Enterprise value
$168.61M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.33
Earnings
Revenue
$127.24M
EBIT
-$130.25M
EBITDA
-$115.89M
Free cash flow
-$133.31M
Per share
EPS
-$1.12
Free cash flow per share
-$1.04
Book value per share
-$0.12
Revenue per share
$0.99
TBVPS
$2.87
Balance sheet
Total assets
$367.7M
Total liabilities
$382.82M
Debt
$212.28M
Equity
-$15.12M
Working capital
$135.17M
Liquidity
Debt to equity
-14.04
Current ratio
2.71
Quick ratio
2.46
Net debt/EBITDA
-0.29
Margins
EBITDA margin
-91.1%
Gross margin
100%
Net margin
-111%
Operating margin
-107.5%
Efficiency
Return on assets
-40.6%
Return on equity
N/A
Return on invested capital
-45.4%
Return on capital employed
-45.1%
Return on sales
-102.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MCRB stock price

How has the Seres Therapeutics stock price performed over time
Intraday
-7.14%
1 week
-7.14%
1 month
-28.28%
1 year
-84%
YTD
-81.43%
QTD
-56.3%

Financial performance

How have Seres Therapeutics's revenue and profit performed over time
Revenue
$127.24M
Gross profit
$127.24M
Operating income
-$136.76M
Net income
-$141.27M
Gross margin
100%
Net margin
-111%
The operating margin has soared by 94% YoY and by 6% from the previous quarter
MCRB's net margin has surged by 94% year-on-year and by 6% since the previous quarter
MCRB's operating income is up by 40% year-on-year and by 8% since the previous quarter
Seres Therapeutics's net income has increased by 39% YoY and by 8% from the previous quarter

Growth

What is Seres Therapeutics's growth rate over time

Valuation

What is Seres Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.05
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.33
The EPS has soared by 52% YoY and by 10% QoQ
The equity has shrunk by 167% QoQ and by 122% YoY
The stock's price to sales (P/S) is 98% less than its last 4 quarters average of 57.9 and 97% less than its 5-year quarterly average of 32.6
MCRB's revenue is down by 2.4% since the previous quarter

Efficiency

How efficient is Seres Therapeutics business performance
The ROS has soared by 94% YoY and by 8% QoQ
The return on invested capital has surged by 75% year-on-year and by 28% since the previous quarter
The company's return on assets rose by 45% YoY and by 12% QoQ

Dividends

What is MCRB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MCRB.

Financial health

How did Seres Therapeutics financials performed over time
The total assets is 4% lower than the total liabilities
The total liabilities has soared by 57% YoY
The quick ratio fell by 22% QoQ and by 17% YoY
MCRB's debt has surged by 179% year-on-year
The equity has shrunk by 167% QoQ and by 122% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.